These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37189413)

  • 1. Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases.
    Braga SS
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclodextrins applied to the treatment of lysosomal storage disorders.
    Ishitsuka Y; Irie T; Matsuo M
    Adv Drug Deliv Rev; 2022 Dec; 191():114617. PubMed ID: 36356931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.
    Coisne C; Tilloy S; Monflier E; Wils D; Fenart L; Gosselet F
    Molecules; 2016 Dec; 21(12):. PubMed ID: 27999408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.
    Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC
    Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease.
    Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T
    Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis.
    Szente L; Singhal A; Domokos A; Song B
    Molecules; 2018 May; 23(5):. PubMed ID: 29783784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
    Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
    Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
    Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
    Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells.
    Egele K; Samaddar S; Schneider N; Thompson D; Wenz G
    J Mater Chem B; 2019 Jan; 7(4):528-537. PubMed ID: 31372225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.
    Calias P
    Curr Pharm Des; 2017; 23(40):6231-6238. PubMed ID: 29065825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactose-Appended Hydroxypropyl-β-Cyclodextrin Lowers Cholesterol Accumulation and Alleviates Motor Dysfunction in Niemann-Pick Type C Disease Model Mice.
    Nishida T; Yokoyama R; Kubohira Y; Maeda Y; Takeo T; Nakagata N; Takagi H; Ishikura K; Yanagihara K; Misumi S; Kishimoto N; Ishitsuka Y; Kondo Y; Irie T; Soga M; Era T; Onodera R; Higashi T; Motoyama K
    ACS Appl Bio Mater; 2022 May; 5(5):2377-2388. PubMed ID: 35506864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
    Tamura A; Yui N
    J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder.
    Brown A; Patel S; Ward C; Lorenz A; Ortiz M; DuRoss A; Wieghardt F; Esch A; Otten EG; Heiser LM; Korolchuk VI; Sun C; Sarkar S; Sahay G
    Sci Rep; 2016 Aug; 6():31750. PubMed ID: 27572704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases.
    Vecsernyés M; Fenyvesi F; Bácskay I; Deli MA; Szente L; Fenyvesi É
    Arch Med Res; 2014 Nov; 45(8):711-29. PubMed ID: 25482528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of 2-Hydroxypropyl-β-Cyclodextrin Treatment in a Neuronal-Like Cell Model of Niemann-Pick Type C Using Quantitative Proteomics.
    Cougnoux A; Pergande MR; Serna-Perez F; Cologna SM
    J Am Soc Mass Spectrom; 2023 Apr; 34(4):668-675. PubMed ID: 36920149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C.
    Puglisi A; Yagci Y
    Macromol Rapid Commun; 2019 Jan; 40(1):e1800557. PubMed ID: 30216584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
    Yamada Y; Miwa T; Nakashima M; Shirakawa A; Ishii A; Namba N; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Okada Y; Ichikawa A; Higaki K; Hayashi K; Minami K; Yoshikawa N; Ikeda R; Ishikawa Y; Kajii T; Tachii K; Takeda H; Orita Y; Matsuo M; Irie T; Ishitsuka Y
    Biomed Pharmacother; 2022 Nov; 155():113698. PubMed ID: 36116252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
    Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
    Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.